GSK boosts oncology rebuild with $11 billion Nuvalent acquisition
British drugmaker GSK has capped its Project Nashville oncology rebuild with an 11 billion dollar acquisition of Nuvalent, Investing.com reported. The deal aims to expand GSK's pipeline in targeted lung cancer therapies, including ROS1 and ALK inhibitors.
Investing.com reported that GSK has agreed to acquire US-based Nuvalent for 11 billion dollars. The transaction is structured as a 95 dollar per share cash offer and was unanimously approved by Nuvalent's board. Chief Executive Emma Walmsley said in a statement that the purchase supports GSK's 2031 revenue trajectory and is the centrepiece of its oncology rebuild.
The report noted that Nuvalent's zorin (ROS1 inhibitor) and ALK programmes are in late-stage trials for non-small cell lung cancer. Under the deal, the Cambridge, Massachusetts-based research team is to be retained. Citi analyst Andrew Baum described the transaction as a richly priced but scientifically high-quality move in oncology consolidation.
According to Reuters, the deal is expected to close in the second half of 2026, with regulatory review running in parallel in the United States, the European Union and the United Kingdom. GSK shares fell 2.3 percent in London following the announcement, while NUVL jumped 38 percent in pre-market trade. This is not investment advice.
Read next
BHP braces for Port Hedland strike that could hit iron ore exports
Australian mining giant BHP is bracing for production disruption at the world's largest iron ore export hub after unionised workers at Port Hedland voted to take protected industrial action. The strike could begin as soon as next week.
New Zealand dairy debt falls by nearly NZ$5 billion as balance-sheet repair strengthens sector
Mike Ashley's Frasers Group offers £1.73 billion to buy Hugo Boss outright
Oracle stock slides after earnings as steep AI spending bill spooks investors
New Zealand agricultural exports set to climb to record NZ$64.3 billion, led by dairy and red meat
